Patents Examined by Titilayo Moloye
  • Patent number: 10597635
    Abstract: Provided is an isolated population of human pluripotent stem cells comprising at least 50% human pluripotent stem cells characterized by an OCT4+/TRA1-60?/TRA1-81?/SSEA1+/SSEA4? expression signature, and novel methods of generating and maintaining same in a pluripotent, undifferentiated state a suspension culture devoid of cell clumps. Also provided are novel culture media, cell cultures and methods for culturing pluripotent stem cells in a suspension culture or a two-dimensional culture system while maintaining the cells in a proliferative, pluripotent and undifferentiated state. The novel culture media comprise interleukin 11 (IL11) and Ciliay Neurotrophic Factor (CNTF); bFGF at a concentration of at least 50 ng/ml and an IL6RIL6 chimera; or an animal contaminant-free serum replacement and an IL6RIL6 chimera. Also provided are methods for generating lineage-specific cells from the pluripotent stem cells.
    Type: Grant
    Filed: January 11, 2017
    Date of Patent: March 24, 2020
    Assignee: Technion Research & Development Foundation Limited
    Inventors: Michal Amit, Joseph Itskovitz-Eldor
  • Patent number: 10590386
    Abstract: The present invention discloses novel compositions and methods for enhancing cardiac differentiation efficiency of stem cells or promoting ventricular and atrial cardiomyocytes formation from stem cells. The present invention also discloses the atrial and ventricular cardiomyocytes formed from the stem cells, and the uses of the cardiomyocytes for repairing cardiac injuries and screening for new medicaments for treating cardiac injuries.
    Type: Grant
    Filed: October 28, 2015
    Date of Patent: March 17, 2020
    Inventor: Yue Ma
  • Patent number: 10584313
    Abstract: The present invention relates generally to the field of somatic cell nuclear transfer (SCNT) and to the creation of cloned animals and cells. The disclosure relates to a method of cloning a mammal, obtaining pluripotent cells such as embryonic stem cells, or for reprogramming a mammalian cell using an oocyte and a fertilized embryo.
    Type: Grant
    Filed: July 23, 2014
    Date of Patent: March 10, 2020
    Assignee: Astellas Institute for Regenerative Medicine
    Inventors: Robert P. Lanza, Young Gie Chung
  • Patent number: 10577430
    Abstract: Mice are provided that comprise a reduction or deletion of ADAM6 activity from an endogenous ADAM6 locus, or that lack an endogenous locus encoding a mouse ADAM6 protein, wherein the mice comprise a sequence encoding an ADAM6 or ortholog or homolog or fragment thereof that is functional in a male mouse. In one embodiment, the sequence is an ectopic ADAM6 sequence or a sequence that confers upon a male mouse the ability to generate offspring by mating. Mice and cells with genetically modified immunoglobulin heavy chain loci that comprise an ectopic nucleotide sequence encoding a mouse ADAM6 or functional fragment or homolog or ortholog thereof are also provided.
    Type: Grant
    Filed: August 9, 2018
    Date of Patent: March 3, 2020
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Lynn Macdonald, Sean Stevens, Andrew J. Murphy, Margaret Karow
  • Patent number: 10568307
    Abstract: Provided herein are compositions comprising non-human animals comprising neurons expressing stabilized step function opsin proteins on neural plasma membranes and methods of using the same to selectively depolarize neurons residing in microcircuits of the pre-frontal cortex to affect one or more social behaviors, communications, and/or conditioned behaviors in the non-human animal.
    Type: Grant
    Filed: November 4, 2011
    Date of Patent: February 25, 2020
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Karl Deisseroth, Ofer Yizhar, Lief Fenno
  • Patent number: 10569099
    Abstract: Stimulation of target cells using light, e.g., in vivo, is implemented using a variety of methods and devices. According to an example embodiment of the present invention, target cells are stimulated using an implantable arrangement. The arrangement includes an electrical light-generation means for generating light and a biological portion. The biological portion has a photosensitive bio-molecular arrangement that responds to the generated light by stimulating target cells in vivo.
    Type: Grant
    Filed: November 10, 2014
    Date of Patent: February 25, 2020
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Karl Deisseroth, M. Bret Schneider, David J. Mishelevich
  • Patent number: 10517731
    Abstract: An anatomically-shaped, human bone graft may be cultivated ex vivo using a bioreactor capable of perfusing large complex porous scaffolds. Scaffolds derived from image-based modeling of a target are seeded with human mesenchymal stem cells and cultivated. A bioreactor configured to house complex three-dimensional scaffold geometries provides controlled flow for perfusion of the cells. Dense uniform cellular growth can be attained throughout the entire scaffold as a result of the medium perfusion. In an embodiment, the bioreactor has a mold into which perfusion medium is pumped under pressure and multiple ports through which the medium exits the mold.
    Type: Grant
    Filed: June 26, 2017
    Date of Patent: December 31, 2019
    Assignee: The Trustees of Columbia University in the City of New York
    Inventors: Gordana Vunjak-Novakovic, Warren Grayson, Keith Yeager
  • Patent number: 10513685
    Abstract: Provided is a method that achieves control of embryoid body size and can induce differentiation in a state where the embryoid body size is controlled, by using a cell culture chamber having a plurality of microchambers formed therein. A culture method for causing differentiation of pluripotent mammalian cells uses a cell culture chamber (10) having a plurality of microchambers (11) formed on a culture surface. The cell culture chamber (10) has a culture surface formed of spaces in which the microchambers (11) have a space structure with a height of 10 ?m to 500 ?m and a bottom area of 100 ?m2 to 1 mm2. The culture method for causing differentiation of pluripotent mammalian cells includes culturing pluripotent mammalian cells to obtain a cell population at least partially differentiated into endoderm lineage cells, by using the cell culture chambers (10).
    Type: Grant
    Filed: March 23, 2011
    Date of Patent: December 24, 2019
    Inventors: Yoko Itchoda, Go Tazaki, Masaya Hosoda, Motohiro Fukuda, Hideki Taniguchi, Yun-Wen Zheng, Keisuke Sekine
  • Patent number: 10507187
    Abstract: A graft containing a scaffold that includes a matrix in which are positioned mesenchymal progenitor cells (MPCs) has the capacity to substantially improve wound healing, including wounds resulting from injury to nerve, bone and vascular tissue. MPCs can be harvested from debrided muscle tissue following orthopaedic trauma. The traumatized muscle-derived progenitor cells are a readily available autologous cell source that can be utilized to effect or improve wound healing in a variety of therapeutic settings and vehicles.
    Type: Grant
    Filed: February 12, 2014
    Date of Patent: December 17, 2019
    Inventors: Wesley M. Jackson, Leon J. Nesti, Rocky S. Tuan
  • Patent number: 10509036
    Abstract: Provided herein are methods for selecting/identifying and/or isolating cancer stem cells from a biological sample or a cell culture sample using a fluorescent glucose analog. Also provided herein are methods for selecting/identifying and/or isolating leukemia stem cells and subpopulations thereof. The present invention is based, in part, on the discovery that cancer stem cells can be selected/identified based upon a lower level of fluorescence of the fluorescent glucose analog compared to non-cancer stem cells and that specific genes are differentially expressed in leukemia stem cells compared to non-leukemia stem cells.
    Type: Grant
    Filed: May 4, 2017
    Date of Patent: December 17, 2019
    Inventors: Noriko Satake, Nitin Nitin
  • Patent number: 10501746
    Abstract: The present invention uses co-expression of protease inhibitors and protease sensitive therapeutic agents including phage and phagemids delivering peptides, therapeutic antibodies, DNA and RNA-based therapeutics that results in treating inflammation of a variety of disorders including psoriasis, atopic dermatitis and inflammatory bowel disease. The invention also provides bacteria that inhibit the growth of intestinal parasites such as worms, and deliver siRNA or miRNA that have specific anti-parasitic effects that results in the reduction or elimination of the parasite.
    Type: Grant
    Filed: March 10, 2017
    Date of Patent: December 10, 2019
    Inventor: David Gordon Bermudes
  • Patent number: 10470446
    Abstract: Embodiments of the disclosure concern compositions and methods for genetic engineering related to hypermethylation of sequences. In particular embodiments, there are methods and compositions to induce DNA methylation in a manner that leads to transcriptional suppression of a target gene that allows characterization of the gene and/or its expression.
    Type: Grant
    Filed: May 21, 2015
    Date of Patent: November 12, 2019
    Assignee: Baylor College of Medicine
    Inventor: Lanlan Shen
  • Patent number: 10451608
    Abstract: A variety of applications, systems, methods and constructs are implemented for use in connection with screening of ion-channel modulators. Consistent with one such system, drug candidates are screened to identify their effects on cell membrane ion channels and pumps. The system includes screening cells having light responsive membrane ion switches, voltage-gated ion switches and fluorescence producing voltage sensors. A chemical delivery device introduces the drug candidates to be screened. An optical delivery device activates the light responsive ion switches. An optical sensor monitors fluorescence produced by the voltage sensors. A processor processes data received from the optical sensor. A memory stores the data received from the optical sensor.
    Type: Grant
    Filed: May 12, 2016
    Date of Patent: October 22, 2019
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Karl Deisseroth, Feng Zhang, Viviana Gradinaru, M. Bret Schneider
  • Patent number: 10434218
    Abstract: A treatment for bioprosthetic tissue used in implants or for assembled bioprosthetic heart valves to reduce in vivo calcification is disclosed. The method includes preconditioning, pre-stressing, or pre-damaging fixed bioprosthetic tissue in a manner that mimics the damage associated with post-implant use, while, and/or subsequently applying a calcification mitigant such as a capping agent or a linking agent to the damaged tissue. The capping agent suppresses the formation of binding sites in the tissue that are exposed or generated by the damage process (service stress) and otherwise would, upon implant, attract calcium, phosphate, immunogenic factors, or other precursors to calcification. The linking agent will act as an elastic reinforcement or shock-absorbing spring element in the tissue structure at the site of damage from the pre-stressing.
    Type: Grant
    Filed: January 24, 2018
    Date of Patent: October 8, 2019
    Assignee: Edwards Lifesciences Corporation
    Inventors: James A. Davidson, Jeffrey S. Dove, Darin P. Dobler
  • Patent number: 10407663
    Abstract: The present invention relates to stem cells obtained from the amnion and their methods of obtaining and culturing. The present invention further relates to compositions comprising amnion-derived stem cells (ADSCs) and to methods of using ADSCs.
    Type: Grant
    Filed: August 10, 2018
    Date of Patent: September 10, 2019
    Inventors: Dale Woodbury, Akiva J. Marcus
  • Patent number: 10400219
    Abstract: Engineered, living, three-dimensional liver tissue constructs including: one or more layers, wherein each layer contains one or more liver cell types, the one or more layers cohered to form a living, three-dimensional liver tissue construct free of pre-formed scaffold. Also disclosed are arrays and methods of making the same.
    Type: Grant
    Filed: May 26, 2016
    Date of Patent: September 3, 2019
    Assignee: Organovo, Inc.
    Inventors: Benjamin R. Shepherd, Justin B. Robbins, Vivian A. Gorgen, Sharon C. Presnell
  • Patent number: 10386361
    Abstract: Hoxb5 identifies long-term hematopoietic stem cells. Expression of Hoxb5 distinguishes between LT-HSCs and non-LT-HSCs, and the marker identifies substantially all LT-HSC in the bone marrow. By utilizing fluorescent proteins under the endogenous expression control of Hoxb5, LT-HSC can be monitored and isolated, including without limitation detection and monitoring of HSC in bone morrow; production of LT-HSC from pluripotent stem cells such as iPS cells; for analysis of early stage LT-HSC; in screening methods for expansion and manipulation of LT-HSC, and the like.
    Type: Grant
    Filed: June 7, 2017
    Date of Patent: August 20, 2019
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: James Y. Chen, Masanori Miyanishi, Irving L. Weissman
  • Patent number: 10377989
    Abstract: The present invention provides methods of preparing aggregated pluripotent stem cell clusters for differentiation.
    Type: Grant
    Filed: December 30, 2013
    Date of Patent: August 13, 2019
    Assignee: Janssen Biotech, Inc.
    Inventors: Benjamin Fryer, Daina Laniauskas, Marcia Blackmoore, Haiyun Wang, Kostadinka LiLova, Shelley Nelson, Elizabeth Rosocha
  • Patent number: 10370644
    Abstract: The present invention provides methods of preparing aggregated pluripotent stem cell clusters for differentiation. Specifically, the invention discloses methods of differentiating pluripotent cells into beta cell, cardiac cell and neuronal cell lineages using suspension clustering. The methods involve preparing the aggregated cell clusters followed by differentiation of these clusters.
    Type: Grant
    Filed: June 17, 2014
    Date of Patent: August 6, 2019
    Assignee: Janssen Biotech, Inc.
    Inventors: Benjamin Fryer, Daina Laniauskas, Marcia Blackmoore, Haiyun Wang, Kostadinka Lilova, Shelley Nelson, Elizabeth Rosocha
  • Patent number: 10370632
    Abstract: In order to culture the pluripotent stem cell which can be variously differentiated, while preventing the cross contamination between the different cells and securing the safety of the products; extending a main transport path 31 outwardly from a stem cell conditioning area 20, the stem cell conditioning area 20 including a treatment room 21 for inducing pluripotent stem cell from a somatic cell or an egg cell, or a treatment room 21 for receiving and conditioning pluripotent stem cell induced in other facilities; branching at least one branched transport path 32 from the main transport path 31; and arranging along each branched transport path 32, a cell culture area 40 including culture rooms 41 to 44 for culturing the stem cell and an analysis room 45 for analyzing the cultured cell, respectively.
    Type: Grant
    Filed: July 11, 2014
    Date of Patent: August 6, 2019
    Assignee: Kajima Corporation
    Inventors: Toshimitsu Fuji, Shigenori Ozaki, Yoshio Kinoshita, Hajime Fujinaga, Ryoji Shiina, Atsushi Nishida